InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,062.45
(
-0.16%
)
US TECH 100
17,027.20
(
0.14%
)
Dow Jones
38,434.56
(
-0.18%
)
Brent Oil
87.19
(
-0.43%
)
Bitcoin
64,184.84
(
-3.35%
)
Post# of 251587
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Double_Bagel

Send PM Follow Ignore
Followers 14
Posts 898
Boards Moderated 0
Alias Born 03/07/2011

Double_Bagel

Re: None

Friday, 02/05/2016 6:29:34 AM

Friday, February 05, 2016 6:29:34 AM

Post# of 251587
Why should one buy EGRX over MNK, AMAG or GILD which all trade at ridiculous P/Es? Both AMAG (at JPM) and MNK beat Q4 and raised 2016 guidance recently.

I think in this environment staying away from Biotechs with no earnings is probably a good idea.

At the same time trying to figure out which cheap Biotech to buy is not easy either. EGRX has the highest forward P/E of the 4 listed below. Is the expectation (here) that this 2016 analyst consensus for EGRX too low?

http://finance.yahoo.com/q/ae?s=EGRX+Analyst+Estimates

http://finance.yahoo.com/q/ae?s=AMAG+Analyst+Estimates

http://finance.yahoo.com/q/ae?s=MNK+Analyst+Estimates

http://finance.yahoo.com/q/ae?s=GILD+Analyst+Estimates

Thanks
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up